AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.64 |
Market Cap | 74.43M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.42 |
PE Ratio (ttm) | -0.45 |
Forward PE | n/a |
Analyst | Hold |
Ask | 0.67 |
Volume | 8,142,045 |
Avg. Volume (20D) | 6,288,604 |
Open | 0.70 |
Previous Close | 0.69 |
Day's Range | 0.62 - 0.73 |
52-Week Range | 0.60 - 10.62 |
Beta | undefined |
About APLT
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the...
Analyst Forecast
According to 6 analyst ratings, the average rating for APLT stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 681.62% from the latest price.
Next Earnings Release
Analysts project revenue of $183.33K, reflecting a -127.49% YoY shrinking and earnings per share of -0.17, making a -57.50% decrease YoY.